Nkarta, Inc.

Report azionario NasdaqGS:NKTX

Capitalizzazione di mercato: US$232.5m

Nkarta Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di Nkarta diminuiranno del 1.7% all'anno, mentre si prevede che il fatturato annuo crescerà del 71.5% all'anno. Si prevede che l'EPS crescerà del 10.6% all'anno.

Informazioni chiave

-1.7%

Tasso di crescita degli utili

10.64%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.4%
Tasso di crescita dei ricavi71.5%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento13 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Nov 22

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Summary Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early preclinical results in B cell depletion and is advancing through Ntrust-1 and Ntrust-2 trials. NKTX boasts a strong cash position, providing over three years of operational runway, supporting continued research and development through key upcoming milestones. While clinical data is delayed to 1H 2026 and risks remain high, the current valuation undervalues NKTX’s potential, justifying a positive outlook. Read the full article on Seeking Alpha
Articolo di analisi • Nov 01

Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Jul 15

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 31

Nkarta: Betting On The Turnaround

Summary Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention. Despite risks, NKTX is significantly undervalued with a potential upside; I plan to buy below $2.50 and target a sell at $7.05. Read the full article on Seeking Alpha
Articolo di analisi • Feb 27

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 02

Nkarta, Inc.: Trying To Find Space In A Crowded Place

Summary Nkarta has ceased development of NKX019 in lymphoma, focusing instead on autoimmune diseases. NKTX has $402.5M in cash and investments, which it estimates will last into late 2027. The name currently trades at less than half of cash. Cell therapy for autoimmune disease is a crowded space, but NKTX's ongoing trials, Ntrust-1 and Ntrust-2, in combination with two investigator sponsored trials, do give it multiple shots on goal. Read the full article on Seeking Alpha
Seeking Alpha • Oct 31

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Summary Nkarta is set to report data from its CAR-NK cell therapy, NKX019, used in a compressed dosing regime in lymphoma patients, in late 2024, possibly with Q3'24 earnings. NKTX seems increasingly focused on the development of NKX019 in autoimmune diseases, with trials of NKX019 in various autoimmune conditions underway already or soon to be underway. The Company faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning chemotherapy. Read the full article on Seeking Alpha
Articolo di analisi • Sep 10

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Nkarta ( NASDAQ:NKTX...
Seeking Alpha • Aug 14

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Summary Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell burden to go after and no tumor microenvironment. Data from the Ntrust-1 study targeting LN patients and results from Ntrust-2 targeting SSC, myositis and vasculitis, expected in 2025. Read the full article on Seeking Alpha
Seeking Alpha • May 23

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. The success of Nkarta's lead program, NKX019, in clinical trials will be crucial for the company's future and potential revenue generation. Read the full article on Seeking Alpha
Seeking Alpha • Apr 27

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Summary NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in oncology with more data coming mid-year. The work in autoimmune disease is just getting underway in H1'24. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Nkarta: NK Cell Therapy Advancement On Two Fronts

Summary Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036. NKX019 is also being used to target patients with autoimmune disorders like Lupus Nephritis; the first patient in the phase 1 study is to be dosed in 1st half of 2024. Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a public offering of $240 million was expected to close in March 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

Nkarta: Possible Upside From H1 Update, If Positive

Summary NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program. NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of 60% in patients with acute myeloid leukemia. The company's focus on a specific lymphodepletion regimen has shown better safety and durability outcomes, positioning them as a leader in the NK cell therapy space. Read the full article on Seeking Alpha
Articolo di analisi • Jan 16

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Oct 04

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Articolo di analisi • Jun 21

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Mar 06

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Nov 20

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Nkarta GAAP EPS of -$0.61

Nkarta press release (NASDAQ:NKTX): Q2 GAAP EPS of -$0.61. Cash and Cash Equivalents: As of June 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $415.0 million.
Articolo di analisi • Jun 09

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 20

Nkarta: A Promising Natural Killer Cell Play

The market has favorably appreciated Nkarta’s recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the actual share price, possibly due to the market’s lack of insight in the highly innovative nature of the science. I give my take on Nkarta’s science, its recent readout, and its competitors. The stock is a long-term buy for me, but I do advise further investment diversificationin similar companies.
Articolo di analisi • Aug 23

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 10

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jan 25

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:NKTX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028N/A-146N/AN/A3
12/31/2027N/A-128N/AN/A4
12/31/2026N/A-117N/AN/A4
3/31/2026N/A-100-88-87N/A
12/31/2025N/A-104-90-89N/A
9/30/2025N/A-103-94-92N/A
6/30/2025N/A-109-100-98N/A
3/31/2025N/A-111-106-101N/A
12/31/2024N/A-109-104-100N/A
9/30/2024N/A-111-108-98N/A
6/30/2024N/A-108-110-94N/A
3/31/2024N/A-116-117-94N/A
12/31/2023N/A-118-114-86N/A
9/30/2023N/A-122-127-70N/A
6/30/2023N/A-125-123-65N/A
3/31/2023N/A-119-110-59N/A
12/31/2022N/A-114-104-57N/A
9/30/2022N/A-104-80-67N/A
6/30/2022N/A-98-78-71N/A
3/31/2022N/A-93-77-72N/A
12/31/2021N/A-86-73-68N/A
9/30/2021N/A-81-68-63N/A
6/30/2021N/A-72-62-57N/A
3/31/2021N/A-102-56-50N/A
12/31/2020N/A-91-51-44N/A
9/30/2020N/A-84-44-37N/A
6/30/20200-73-36-30N/A
3/31/20200-27-27-23N/A
12/31/20190-21N/A-18N/A
12/31/201870N/A-5N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che NKTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che NKTX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che NKTX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che NKTX non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che NKTX non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di NKTX è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/31 00:49
Prezzo dell'azione a fine giornata2026/05/29 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Nkarta, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
William MaughanCanaccord Genuity
Joshua SchimmerEvercore ISI
Emily BodnarH.C. Wainwright & Co.